Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3974 · 1 trial · 1 indication
To assess the safety and tolerability of AZD3974 following oral administration of single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
| Arm | Type | Description |
|---|---|---|
| Part A1 (SAD) Cohort 1: AZD3974 (Dose 1) | EXPERIMENTAL | Healthy participants will receive a single dose of AZD3974 - Dose 1 |
| Part A1 (SAD) Cohort 2: AZD3974 (Dose 2) | EXPERIMENTAL | Healthy participants will receive a single dose of AZD3974 - Dose 2 |
| Part A1 (SAD) Cohort 3: AZD3974 (Dose 3) (Food Effect Cohort) | EXPERIMENTAL | Healthy participants will receive two single doses of AZD3974 - Dose 3 |
| Part A1 (SAD) Cohort 4: AZD3974 (Dose 4) | EXPERIMENTAL | Healthy participants will receive a single dose of AZD3974 - Dose 4 |
| Part A1 (SAD) Cohort 5: AZD3974 (Dose 5) | EXPERIMENTAL | Healthy participants will receive a single dose of AZD3974 - Dose 5 |
| Part A1 (SAD) Cohort 6: AZD3974 (Dose 6) | EXPERIMENTAL | Healthy participants will receive a single dose of AZD3974 - Dose 6 |
| Part A1 (SAD) optional additional Cohort 7: AZD3974 | EXPERIMENTAL | Healthy participants will receive a single dose of AZD3974 |
| Part A1 (SAD) optional additional Cohort 8: AZD3974 | EXPERIMENTAL | Healthy participants will receive a single dose of AZD3974 |
| Part A1 (SAD) Cohort: Placebo | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of matching placebo to AZD3974 |
| Part A1 (SAD) Cohort 3: Placebo (Food Effect Cohort) | PLACEBO_COMPARATOR | Healthy participants will receive two single doses of matching placebo to AZD3974 |
| Part A2 (SAD) Japanese Cohort 1: AZD3974 | EXPERIMENTAL | Healthy Japanese participants will receive a single dose of AZD3974 |
| Part A2 (SAD) Japanese Cohort 2: AZD3974 | EXPERIMENTAL | Healthy Japanese participants will receive a single dose of AZD3974 |
| Part A2 (SAD) Japanese Cohort 3: AZD3974 | EXPERIMENTAL | Healthy Japanese participants will receive a single dose of AZD3974 |
| Part A2 (SAD) optional additional Japanese Cohort 4: AZD3974 | EXPERIMENTAL | Healthy Japanese participants will receive a single dose of AZD3974 |
| Part A2 (SAD) Japanese Cohort: Placebo | PLACEBO_COMPARATOR | Healthy Japanese participants will receive a single dose of matching placebo to AZD3974 |
| Part A3 (SAD) Chinese Cohort 1: AZD3974 | EXPERIMENTAL | Healthy Chinese participants will receive a single dose of AZD3974 |
| Part A3 (SAD) optional additional Chinese Cohort 2: AZD3974 | EXPERIMENTAL | Healthy Chinese participants will receive a single dose of AZD3974 |
| Part A3 (SAD) Chinese Cohort: Placebo | PLACEBO_COMPARATOR | Healthy Chinese participants will receive a single dose of matching placebo to AZD3974 |
| Part B1 (MAD) Cohort 1: AZD3974 | EXPERIMENTAL | Healthy participants will receive multiple doses of AZD3974 |
| Part B1 (MAD) Cohort 2: AZD3974 | EXPERIMENTAL | Healthy participants will receive multiple doses of AZD3974 |
| Part B1 (MAD) Cohort 3: AZD3974 | EXPERIMENTAL | Healthy participants will receive multiple doses of AZD3974 |
| Part B1 (MAD) Cohort 4: AZD3974 | EXPERIMENTAL | Healthy participants will receive multiple doses of AZD3974 |
| Part B1 (MAD) optional additional Cohort 5: AZD3974 | EXPERIMENTAL | Healthy participants will receive multiple doses of AZD3974 |
| Part B1 (MAD) optional additional Cohort 6: AZD3974 | EXPERIMENTAL | Healthy participants will receive multiple doses of AZD3974 |
| Part Bl (MAD) Cohort: Placebo | PLACEBO_COMPARATOR | Healthy participants will receive multiple doses of matching placebo to AZD3974 |
| Part B2 (MAD) Japanese Cohort 1: AZD3974 | EXPERIMENTAL | Healthy Japanese participants will receive multiple doses of AZD397 |
| Part B2 (MAD) optional additional Japanese Cohort 2: AZD3974 | EXPERIMENTAL | Healthy Japanese participants will receive multiple doses of matching placebo to AZD3974 |
| Part B2 (MAD) Japanese Cohort: Placebo | PLACEBO_COMPARATOR | Healthy Japanese participants will receive multiple doses of matching placebo to AZD3974 |
| Name | Type | Description |
|---|---|---|
| AZD3974 | DRUG | AZD3974 will be administered as an oral solution. |
| Placebo | OTHER | Placebo will be administered as an oral solution. |
Inclusion Criteria: * Healthy male and female (of non-childbearing potential) participants with suitable veins for cannulation or repeated venipuncture at the Screening Visit. * All females must have a negative pregnancy test. Females of non-childbearing potential must be confirmed via post-menopau...
AZD3974 is an investigational small molecule being developed by AstraZeneca PLC. It is in Phase 1 clinical development, with a single active trial currently recruiting healthy adult participants in the United States. The specific disease or condition it is intended to treat has not been disclosed.
AZD3974 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the Phase 1 trial evaluating the compound in healthy participants.
AZD3974 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA. One Phase 1 trial is currently active and recruiting, with no completed trials reported for this asset.
AZD3974 is being studied in one Phase 1 trial, NCT07290283, titled a study to investigate safety, tolerability, and pharmacokinetics of AZD3974 in healthy participants. The trial is recruiting, is placebo controlled, and is expected to enroll 176 healthy adult volunteers in the United States.
The AZD3974 Phase 1 trial, NCT07290283, is a randomized, placebo-controlled study in healthy participants. It is not double blind and is not biomarker selected. It plans to enroll 176 adults aged 18 years and older of all sexes in the United States, and it is currently recruiting.